FORT LAUDERDALE, Fla. / Feb 11, 2025 / Business Wire / Pediatrix® Medical Group, Inc. (NYSE: MD), a leading provider of physician services, is pleased to announce NEO: The Conference for Neonatology, a premier educational event dedicated to advancing the field of neonatology. The conference will be held Feb. 19-21 in Las Vegas, Nevada, and will bring together neonatologists, pediatricians, advanced practitioners and allied health professionals from around the globe.
As a trusted provider of neonatology services for more than 45 years, Pediatrix cares for nearly a quarter of the infants born in the United States that require intensive care.
The March of Dimes’ 2024 Report Card, released in November, reported that the nation’s preterm birth rate remains historically high at 10.4%, with 370,000 babies born prematurely in 2023. In 2022, the rate was 10.5%. The U.S. earned a D+ for the third consecutive year, remaining the worst grade in the report’s history.
“These findings emphasize the need for continuous innovation in the field of neonatal-perinatal medicine,” said Timothy Biela, M.D., neonatologist at Pediatrix Neonatology of San Antonio and director of the NEO conference. “We are proud to lead research efforts and provide continuing education opportunities not only for our affiliated clinicians, but for all providers of this highly specialized care. Our hope is to improve outcomes for our youngest and most vulnerable patients.”
About the Conference
Now in its 46th year, the NEO conference addresses the latest advancements, research and best practices in neonatology. The meeting aims to provide a platform for knowledge exchange, professional development and collaboration among health care professionals dedicated to the care of newborns.
The comprehensive program includes:
Keynote Speakers
The NEO conference will feature an impressive lineup of keynote speakers, including renowned experts in the field of neonatology. Among the distinguished speakers are:
These thought leaders will share their insights on groundbreaking research, innovative treatments and emerging trends in neonatal care.
Legends of Neonatology
Established in 2007, the Legends of Neonatology award honors remarkable individuals whose clinical contributions have helped forge new ground in neonatal medicine. This year’s recipient is David K. Stevenson, M.D., Harold K. Faber Professor of Pediatrics, Senior Associate Dean for Maternal and Child Health at the Stanford University School of Medicine and Principal Investigator of the Prematurity Research Center. Over the span of four decades, Dr. Stevenson has been at the forefront of research, professional education and clinical care in neonatology. He has made pioneering contributions to neonatology and pediatrics through extensive research in bilirubin biochemistry, heme oxygenase biology and neonatal jaundice. His work has led to new technologies and standards of care for the treatment of neonatal jaundice.
Accredited Continuing Education
Participants attending the NEO conference will have the opportunity to earn accredited continuing education credits. The Pediatrix CREQS is accredited by:
About Pediatrix Medical Group
Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Specialties include obstetrics, maternal-fetal medicine and neonatology. The group’s high-quality, evidence-based care is bolstered by significant investments in research, education, quality improvement and safety initiatives. The physician-led company was founded in 1979 as a single neonatology practice and today provides its highly specialized and often critical care services through approximately 4,400 affiliated physicians and other clinicians. To learn more about Pediatrix, visit www.pediatrix.com or follow us on Facebook, Instagram, LinkedIn and the Pediatrix blog. Investment information can be found at www.pediatrix.com/investors.
Last Trade: | US$12.82 |
Daily Change: | -0.32 -2.44 |
Daily Volume: | 458,724 |
Market Cap: | US$1.100B |
February 20, 2025 November 01, 2024 August 06, 2024 May 07, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load